ANEBULO PHARMACEUTICALS INC (ANEB) Stock Analyst Earnings Estimates
NASDAQ:ANEB - Nasdaq - US0345691036 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A -100.00% | N/A | N/A | N/A | N/A 159.56% | ||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -170K | -3.61M -2,023.53% | -6.83M -89.20% | -11.78M -72.47% | -8.309M 29.47% | N/A -15.19% | N/A -141.32% | N/A 13.55% | N/A -3.23% | N/A -15.89% | N/A -20.73% | N/A 89.25% | N/A 1,429.00% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A 56.45% | -0.47 -70.66% | -0.32 31.91% | N/A 7.56% | N/A -65.52% | N/A 4.17% | N/A 230.43% | N/A 170.00% | N/A 62.35% | N/A 35.36% | N/A |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.07 -32.60% | -0.12 -53.00% | -0.13 -47.33% | -0.14 -257.00% |
| Revenue Q2Q % growth | N/A | N/A | N/A | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.333M -74.09% | -3.415M -41.58% | -3.564M -37.70% | -3.861M -104.02% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | -0.04 33.33% | -0.05 | 0.01 | 21.57% |
| Q2 2025 Q2Q % growth | -0.09 18.18% | -0.08 | -0.01 | -10.29% |
| Q1 2025 Q2Q % growth | -0.08 20.00% | -0.05 | -0.03 | -56.86% |
| Q4 2024 Q2Q % growth | -0.05 50.00% | -0.13 | 0.08 | 62.44% |
| Q3 2024 Q2Q % growth | -0.06 45.45% | -0.12 | 0.06 | 50.15% |
| Q2 2024 Q2Q % growth | -0.11 26.67% | -0.10 | -0.01 | -7.84% |
| Q1 2024 Q2Q % growth | -0.10 9.09% | -0.12 | 0.02 | 15.97% |
| Q4 2023 Q2Q % growth | -0.10 | -0.11 | 0.01 | 11.41% |
| Q3 2023 Q2Q % growth | -0.11 -37.50% | -0.16 | 0.05 | 31.31% |
| Q2 2023 Q2Q % growth | -0.15 -200.00% | -0.11 | -0.04 | -33.69% |
| Q1 2023 Q2Q % growth | -0.11 | -0.11 | 0.00 | -2.71% |
| Q4 2022 Q2Q % growth | -0.10 28.57% | -0.08 | -0.02 | -30.72% |
| Q3 2022 Q2Q % growth | -0.08 88.41% | -0.05 | -0.03 | -56.86% |
| Q2 2022 Q2Q % growth | -0.05 | -0.06 | 0.01 | 18.30% |
| Q4 2021 Q2Q % growth | -0.14 | -0.03 | -0.11 | -357.52% |
| Q3 2021 Q2Q % growth | -0.69 | -0.07 | -0.62 | -866.39% |
| Q1 2021 Q2Q % growth | -0.69 | -0.04 | -0.65 | -1,591.18% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -30% | 0% | -11.54% |
| Revenue | N/A | N/A | N/A | N/A |